- feeds
- popular
- recent
- reader
- about
- story
- technologies
- what is rss
- connect
- dmca
- contact
- Feed Preview NeurologyLive articles
Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD
The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology...
Stealth BioTherapeutics’ SBT-589 Shows Cardioprotective Effects in Preclinical Models of Friedreich Ataxia
Recent preclinical findings revealed SBT-589's potential to treat cardiomyopathy in Friedreich ataxia by targeting mitochondrial dysfunction.
Using a Blood Collection Device to Advance Genetic Research in Parkinson Disease: James Beck, PhD & Ben Casavant, PhD
The chief scientific officer of the Parkinson’s Foundation and chief executive officer of Tasso discussed their company partnership to expand and accelerate genetic research in Parkinson Diseas...
Episode 114: AMX0035, Phase 3 PHOENIX Study, and Amylyx's Future Drug Development
Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Justin Klee and Josh Cohen.
Advancing Tardive Dyskinesia Treatment With New Sprinkle Formulation of Valbenazine
Leslie Citrome, MD, MPH, clinical professor of psychiatry and behavioral sciences at New York Medical College, shared his reaction to the recently approved new sprinkle formulation of valbenazine...
https://www.neurologylive.com/view/advancing-td-treatment-new-sprinkle-formulation-valbenazine
Investigational Pump Agents to Treat Parkinson Disease
In this segment, Kremens described pump therapies currently in development, such as ND0612 and ABBV-951.
https://www.neurologylive.com/view/investigational-pump-agents-treat-parkinson-disease
Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods
Tanisha Hill-Jarrett, PhD, an assistant professor of neurology at the University of California, San Francisco Memory and Aging Center, discussed the change needed to improve cognitive decline rat...
Emerging Novel Therapies in Development for PD
Kremens gave thoughts on the use of several investigational continuous agents, including IPX203, risvodetinib, and P2B001.
https://www.neurologylive.com/view/emerging-novel-therapies-in-development-for-pd
Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD
The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly appr...
First Patient Dosed in Phase 2 Open Label Extension Study of Nomlabofusp for Friedreich Ataxia
Data from the phase 2 open label extension study investigating subcutaneous injections of nomlabofusp for Friedreich ataxia is expected in the fourth quarter of 2024.
Alzheon Initiates Open-Label Extensions for Phase 2 and 3 Studies of Alzheimer Agent ALZ-801
Phase 2 biomarker trial participants who completed 156 weeks of treatment were offered enrollment into another 52-week extension to continue to observe safety, assessments of plasma biomarkers, a...
Special Episode: FDA Approves Diazepam Buccal Film for Pediatric Seizures
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Michael Rogawski, MD, PhD.
Leveraging Artificial Intelligence to Redefine Clinical Eff...eurologists: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN
The neurologist at Mass General Hospital talked about leveraging artificial intelligence to enhance clinical practice amidst growing demands and workforce shortages in neurology.
Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
In the phase 3 OCARINA 2 trial, subcutaneous ocrelizumab was non-inferior to intravenous infusion based on concentration levels in the blood, as well as comparable efficacy on relapses and brain ...
NeurologyLive and CMSC Announce the 3rd Annual Giants of MS Class of Inductees
The award ceremony is supported by EMD Serono and Viatris and will take place on Thursday, May 30, 2024, at the Nashville Music City Center in Nashville, Tennessee, during the 2024 CMSC Annual Me...
https://www.neurologylive.com/view/neurologylive-cmsc-announce-3rd-giants-ms-class-inductees
Latest Findings on AXS-05 Treatment for Agitation in Alzheimer Disease: Anton P. Porsteinsson, MD
The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation ...
NeuroVoices: Eoin P. Flanagan, MB, BCh, on the Potential Significance of Spinal Fluid Testing for MOGAD Diagnosis
The professor of neurology at Mayo Clinic talked about the need for comprehensive testing, careful consideration of criteria for diagnosis, and effective treatment in MOG antibody-associated dise...
Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia Care
Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a spe...
FDA Approves Sprinkle Formulation of Neurocrine Biosciences...albenazine for Tardive Dyskinesia or Huntington disease Chorea
The original approval for chorea associated with Huntington disease was based on the phase 3 KINECT-HD study, an 128-patient cohort trial in which valbenazine met its primary end point.
FDA Approves Medtronic’s Inceptiv Closed-Loop Spinal Cord Stimulator
The FDA approval of Medtronic’s spinal cord stimulator makes it the first on the market to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adj...
Utilizing the SCACOMS Composite Measure to Assess Treatment...it of Troriluzole in Spinocerebellar Ataxia: Irfan Qureshi, MD
The chief medical officer at Biohaven provided insight on its investigational spinocerebellar ataxia agent troriluzole, the advantages of the newly developed SCACOMS measure, and how the therapy ...
Emerging Treatments in MG
Neurology experts provide an overview of emerging treatments in MG, highlighting biomarkers and new routes of administration.
https://www.neurologylive.com/view/emerging-treatments-in-mg
Treatment Adherence in MG
Experts in neurology discuss how to ensure disease progression in not due to poor adherence to treatment in MG, emphasizing educating the patient about their disease.
https://www.neurologylive.com/view/treatment-adherence-in-mg
MOG-Antibody Testing and the Search for Effective Treatment in MOGAD: Eoin P. Flanagan, MB, BCh
The professor of neurology at Mayo Clinic discussed the importance of standardizing MOG- antibody testing techniques and the need for effective treatments in patients living with MOGAD.
AI-Powered Neurotech Could Revolutionize Dementia Care and Unlock Communications
Neal K. Shah, CEO of CareYaya Health Technologies, discussed how emerging neurotechnology, such as mobile EEG devices paired with customized AI and machine learning models, is poised to transform...
Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments
In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relaps...
Complement Inhibitors Ravulizumab and Eculizumab Impact Measures of Neuroaxonal Damage
Ravulizumab reduced NfL levels in cerebrospinal fluid and serum whereas eculizumab showed no change in NfL when compared with placebo.
The Importance of Lifestyle Changes in Multiple Sclerosis Care
Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, review the benefits of exercise and physical activity in patients with MS. They also discuss strategies f...
https://www.neurologylive.com/view/the-importance-of-lifestyle-changes-in-multiple-sclerosis-care
Bladder Management and Patient-Reported Outcomes in Multiple Sclerosis Management
Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the importance of monitoring bladder dysfunction symptoms in MS care.
Diazepam Buccal Film’s Role in Treating Intermittent Pediatric Seizures, with Michael Rogawski, MD, PhD
The professor of neurology and pharmacology at the University of California Davis Health Medical Center gave commentary on the FDA approval of Aquestive Therapeutics’ buccal film in pediatric p...